Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Brand Name : LC350189
Molecule Type : Small molecule
Upfront Cash : $10.0 million
December 14, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LG Chem Enters Final Stage of Clinical Development for New Gout Drug
Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...
Brand Name : LC350189
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?